-
2
-
-
0030031845
-
Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
-
Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med. 1996;334:231-8.
-
(1996)
N Engl J Med
, vol.334
, pp. 231-238
-
-
Norris, M.D.1
Bordow, S.B.2
Marshall, G.M.3
Haber, P.S.4
Cohn, S.L.5
Haber, M.6
-
3
-
-
33645830172
-
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
-
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455:152-62.
-
(1976)
Biochim Biophys Acta
, vol.455
, pp. 152-162
-
-
Juliano, R.L.1
Ling, V.2
-
4
-
-
0022972654
-
Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells
-
Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986;47:381-9.
-
(1986)
Cell
, vol.47
, pp. 381-389
-
-
Chen, C.J.1
Chin, J.E.2
Ueda, K.3
Clark, D.P.4
Pastan, I.5
Gottesman, M.M.6
Roninson, I.B.7
-
5
-
-
0031158805
-
The physiological function of drug-transporting P-glycoproteins
-
Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 1997;8:161-70.
-
(1997)
Semin Cancer Biol
, vol.8
, pp. 161-170
-
-
Schinkel, A.H.1
-
6
-
-
0032754284
-
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
-
Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest. 1999;104:147-53.
-
(1999)
J Clin Invest
, vol.104
, pp. 147-153
-
-
Greiner, B.1
Eichelbaum, M.2
Fritz, P.3
Kreichgauer, H.P.4
Richter, O.5
Zundler, J.6
Kroemer, H.K.7
-
7
-
-
0033980182
-
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs
-
Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000;38:69-74.
-
(2000)
Int J Clin Pharmacol Ther
, vol.38
, pp. 69-74
-
-
Fromm, M.F.1
-
8
-
-
0037022006
-
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
-
Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-6.
-
(2002)
Lancet
, vol.359
, pp. 30-36
-
-
Fellay, J.1
Marzolini, C.2
Meaden, E.R.3
Back, D.J.4
Buclin, T.5
Chave, J.P.6
Decosterd, L.A.7
Furrer, H.8
Opravil, M.9
Pantaleo, G.10
-
9
-
-
84925650964
-
Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics
-
Sadhasivam S, Chidambaran V, Zhang X, Meller J, Esslinger H, Zhang K, Martin LJ, McAuliffe J. Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics. Pharmacogenomics J. 2015;15:119-26.
-
(2015)
Pharmacogenomics J
, vol.15
, pp. 119-126
-
-
Sadhasivam, S.1
Chidambaran, V.2
Zhang, X.3
Meller, J.4
Esslinger, H.5
Zhang, K.6
Martin, L.J.7
McAuliffe, J.8
-
10
-
-
84907178152
-
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance
-
Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014;10:1337-54.
-
(2014)
Expert Opin Drug Metab Toxicol
, vol.10
, pp. 1337-1354
-
-
Bruhn, O.1
Cascorbi, I.2
-
11
-
-
84933673958
-
Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature
-
Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet. 2015;54:709-35.
-
(2015)
Clin Pharmacokinet
, vol.54
, pp. 709-735
-
-
Wolking, S.1
Schaeffeler, E.2
Lerche, H.3
Schwab, M.4
Nies, A.T.5
-
12
-
-
0035805536
-
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin
-
Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276:14581-7.
-
(2001)
J Biol Chem
, vol.276
, pp. 14581-14587
-
-
Geick, A.1
Eichelbaum, M.2
Burk, O.3
-
13
-
-
0022552455
-
Cyclosporine-A reverses vincristine and daunorubicin resistance in acute lymphatic-leukemia in vitro
-
Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporine-A reverses vincristine and daunorubicin resistance in acute lymphatic-leukemia in vitro. J Clin Investig. 1986;77:1405-8.
-
(1986)
J Clin Investig
, vol.77
, pp. 1405-1408
-
-
Slater, L.M.1
Sweet, P.2
Stupecky, M.3
Gupta, S.4
-
14
-
-
0019430432
-
Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil
-
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41:1967-72.
-
(1981)
Cancer Res
, vol.41
, pp. 1967-1972
-
-
Tsuruo, T.1
Iida, H.2
Tsukagoshi, S.3
Sakurai, Y.4
-
15
-
-
0034724324
-
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
-
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-8.
-
(2000)
Proc Natl Acad Sci U S A
, vol.97
, pp. 3473-3478
-
-
Hoffmeyer, S.1
Burk, O.2
Richter, O.3
Arnold, H.P.4
Brockmoller, J.5
Johne, A.6
Cascorbi, I.7
Gerloff, T.8
Roots, I.9
Eichelbaum, M.10
Brinkmann, U.11
-
16
-
-
0034771497
-
MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects
-
Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res. 2001;18:1400-4.
-
(2001)
Pharm Res
, vol.18
, pp. 1400-1404
-
-
Sakaeda, T.1
Nakamura, T.2
Horinouchi, M.3
Kakumoto, M.4
Ohmoto, N.5
Sakai, T.6
Morita, Y.7
Tamura, T.8
Aoyama, N.9
Hirai, M.10
-
17
-
-
0034751938
-
Effect of grapefruit juice on digoxin pharmacokinetics in humans
-
Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther. 2001;70:311-6.
-
(2001)
Clin Pharmacol Ther
, vol.70
, pp. 311-316
-
-
Becquemont, L.1
Verstuyft, C.2
Kerb, R.3
Brinkmann, U.4
Lebot, M.5
Jaillon, P.6
Funck-Brentano, C.7
-
18
-
-
0034744113
-
No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients
-
von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem. 2001;47:1048-52.
-
(2001)
Clin Chem
, vol.47
, pp. 1048-1052
-
-
Ahsen, N.1
Richter, M.2
Grupp, C.3
Ringe, B.4
Oellerich, M.5
Armstrong, V.W.6
-
19
-
-
0036001238
-
C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects
-
Min DI, Ellingrod VL. C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit. 2002;24:400-4.
-
(2002)
Ther Drug Monit
, vol.24
, pp. 400-404
-
-
Min, D.I.1
Ellingrod, V.L.2
-
20
-
-
0035999902
-
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine
-
Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum M, Fromm MF. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002;53:526-34.
-
(2002)
Br J Clin Pharmacol
, vol.53
, pp. 526-534
-
-
Drescher, S.1
Schaeffeler, E.2
Hitzl, M.3
Hofmann, U.4
Schwab, M.5
Brinkmann, U.6
Eichelbaum, M.7
Fromm, M.F.8
-
21
-
-
0037955805
-
Digoxin pharmacokinetics and MDR1 genetic polymorphisms
-
Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 2003;58:809-12.
-
(2003)
Eur J Clin Pharmacol
, vol.58
, pp. 809-812
-
-
Verstuyft, C.1
Schwab, M.2
Schaeffeler, E.3
Kerb, R.4
Brinkmann, U.5
Jaillon, P.6
Funck-Brentano, C.7
Becquemont, L.8
-
22
-
-
33748211157
-
Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1)
-
Wang D, Sadee W. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J. 2006;8:E515-20.
-
(2006)
AAPS J
, vol.8
, pp. E515-E520
-
-
Wang, D.1
Sadee, W.2
-
23
-
-
33846504706
-
A "silent" polymorphism in the MDR1 gene changes substrate specificity
-
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525-8.
-
(2007)
Science
, vol.315
, pp. 525-528
-
-
Kimchi-Sarfaty, C.1
Oh, J.M.2
Kim, I.W.3
Sauna, Z.E.4
Calcagno, A.M.5
Ambudkar, S.V.6
Gottesman, M.M.7
-
24
-
-
64649101364
-
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function
-
Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009;1794:860-71.
-
(2009)
Biochim Biophys Acta
, vol.1794
, pp. 860-871
-
-
Fung, K.L.1
Gottesman, M.M.2
-
25
-
-
3042772026
-
Identification of functionally variant MDR1 alleles among European Americans and African Americans
-
Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-99.
-
(2001)
Clin Pharmacol Ther
, vol.70
, pp. 189-199
-
-
Kim, R.B.1
Leake, B.F.2
Choo, E.F.3
Dresser, G.K.4
Kubba, S.V.5
Schwarz, U.I.6
Taylor, A.7
Xie, H.G.8
McKinsey, J.9
Zhou, S.10
-
26
-
-
10744222684
-
Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene
-
Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13:481-94.
-
(2003)
Pharmacogenetics
, vol.13
, pp. 481-494
-
-
Kroetz, D.L.1
Pauli-Magnus, C.2
Hodges, L.M.3
Huang, C.C.4
Kawamoto, M.5
Johns, S.J.6
Stryke, D.7
Ferrin, T.E.8
DeYoung, J.9
Taylor, T.10
-
27
-
-
0345299165
-
Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells
-
Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999;55:929-37.
-
(1999)
Mol Pharmacol
, vol.55
, pp. 929-937
-
-
Cui, Y.1
Konig, J.2
Buchholz, J.K.3
Spring, H.4
Leier, I.5
Keppler, D.6
-
28
-
-
0033032730
-
Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma
-
Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G, Storkel S, Thon WF, Keppler D. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol. 1999;10:1159-69.
-
(1999)
J Am Soc Nephrol
, vol.10
, pp. 1159-1169
-
-
Schaub, T.P.1
Kartenbeck, J.2
Konig, J.3
Spring, H.4
Dorsam, J.5
Staehler, G.6
Storkel, S.7
Thon, W.F.8
Keppler, D.9
-
29
-
-
0032986770
-
Molecular aspects of organic compound transport across the plasma membrane of hepatocytes
-
Kamisako T, Gabazza EC, Ishihara T, Adachi Y. Molecular aspects of organic compound transport across the plasma membrane of hepatocytes. J Gastroenterol Hepatol. 1999;14:405-12.
-
(1999)
J Gastroenterol Hepatol
, vol.14
, pp. 405-412
-
-
Kamisako, T.1
Gabazza, E.C.2
Ishihara, T.3
Adachi, Y.4
-
30
-
-
84896104969
-
The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia
-
Keppler D. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos. 2014;42:561-5.
-
(2014)
Drug Metab Dispos
, vol.42
, pp. 561-565
-
-
Keppler, D.1
-
31
-
-
44949184483
-
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2)
-
Pedersen JM, Matsson P, Bergstrom CA, Norinder U, Hoogstraate J, Artursson P. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem. 2008;51:3275-87.
-
(2008)
J Med Chem
, vol.51
, pp. 3275-3287
-
-
Pedersen, J.M.1
Matsson, P.2
Bergstrom, C.A.3
Norinder, U.4
Hoogstraate, J.5
Artursson, P.6
-
32
-
-
33750346955
-
Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients
-
Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006;82:1074-84.
-
(2006)
Transplantation
, vol.82
, pp. 1074-1084
-
-
Naesens, M.1
Kuypers, D.R.2
Verbeke, K.3
Vanrenterghem, Y.4
-
33
-
-
49949100063
-
Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers
-
Levesque E, Benoit-Biancamano MO, Delage R, Couture F, Guillemette C. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics. 2008;9:869-79.
-
(2008)
Pharmacogenomics
, vol.9
, pp. 869-879
-
-
Levesque, E.1
Benoit-Biancamano, M.O.2
Delage, R.3
Couture, F.4
Guillemette, C.5
-
34
-
-
84883188340
-
Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients
-
Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients. Clin Pharmacokinet. 2013;52:751-62.
-
(2013)
Clin Pharmacokinet
, vol.52
, pp. 751-762
-
-
Ogasawara, K.1
Chitnis, S.D.2
Gohh, R.Y.3
Christians, U.4
Akhlaghi, F.5
-
35
-
-
33846632909
-
CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
-
Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, Cascorbi I. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther. 2007;81:228-34.
-
(2007)
Clin Pharmacol Ther
, vol.81
, pp. 228-234
-
-
Renders, L.1
Frisman, M.2
Ufer, M.3
Mosyagin, I.4
Haenisch, S.5
Ott, U.6
Caliebe, A.7
Dechant, M.8
Braun, F.9
Kunzendorf, U.10
Cascorbi, I.11
-
36
-
-
84865415281
-
Drug interaction studies--study design, data analysis, implications for dosing, and labeling recommendations
-
FDA. Drug interaction studies--study design, data analysis, implications for dosing, and labeling recommendations. 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.
-
(2012)
-
-
-
37
-
-
77949392921
-
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation
-
Ma JD, Tsunoda SM, Bertino Jr JS, Trivedi M, Beale KK, Nafziger AN. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 2010;49:223-37.
-
(2010)
Clin Pharmacokinet
, vol.49
, pp. 223-237
-
-
Ma, J.D.1
Tsunoda, S.M.2
Bertino, J.S.3
Trivedi, M.4
Beale, K.K.5
Nafziger, A.N.6
-
38
-
-
0028046576
-
Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum
-
Oertel R, Richter K, Trausch B, Berndt A, Gramatte T, Kirch W. Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. J Chromatogr B Biomed Appl. 1994;660:353-63.
-
(1994)
J Chromatogr B Biomed Appl
, vol.660
, pp. 353-363
-
-
Oertel, R.1
Richter, K.2
Trausch, B.3
Berndt, A.4
Gramatte, T.5
Kirch, W.6
-
39
-
-
0029012285
-
Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man
-
Trausch B, Oertel R, Richter K, Gramatte T. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos. 1995;16:403-14.
-
(1995)
Biopharm Drug Dispos
, vol.16
, pp. 403-414
-
-
Trausch, B.1
Oertel, R.2
Richter, K.3
Gramatte, T.4
-
40
-
-
84862908847
-
Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases
-
Chu X, Zhang Z, Yabut J, Horwitz S, Levorse J, Li XQ, Zhu L, Lederman H, Ortiga R, Strauss J, et al. Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases. Mol Pharmacol. 2012;81:220-7.
-
(2012)
Mol Pharmacol
, vol.81
, pp. 220-227
-
-
Chu, X.1
Zhang, Z.2
Yabut, J.3
Horwitz, S.4
Levorse, J.5
Li, X.Q.6
Zhu, L.7
Lederman, H.8
Ortiga, R.9
Strauss, J.10
-
41
-
-
0032823160
-
Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil
-
Gramatte T, Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther. 1999;66:239-45.
-
(1999)
Clin Pharmacol Ther
, vol.66
, pp. 239-245
-
-
Gramatte, T.1
Oertel, R.2
-
42
-
-
4544383423
-
Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans
-
Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004;76:192-200.
-
(2004)
Clin Pharmacol Ther
, vol.76
, pp. 192-200
-
-
Giessmann, T.1
May, K.2
Modess, C.3
Wegner, D.4
Hecker, U.5
Zschiesche, M.6
Dazert, P.7
Grube, M.8
Schroeder, E.9
Warzok, R.10
-
43
-
-
0033753435
-
Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction
-
Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther. 2000;68:345-55.
-
(2000)
Clin Pharmacol Ther
, vol.68
, pp. 345-355
-
-
Westphal, K.1
Weinbrenner, A.2
Zschiesche, M.3
Franke, G.4
Knoke, M.5
Oertel, R.6
Fritz, P.7
Richter, O.8
Warzok, R.9
Hachenberg, T.10
-
44
-
-
34247244726
-
Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol
-
Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther. 2007;81:669-78.
-
(2007)
Clin Pharmacol Ther
, vol.81
, pp. 669-678
-
-
Schwarz, U.I.1
Hanso, H.2
Oertel, R.3
Miehlke, S.4
Kuhlisch, E.5
Glaeser, H.6
Hitzl, M.7
Dresser, G.K.8
Kim, R.B.9
Kirch, W.10
-
45
-
-
16344378672
-
Grapefruit juice ingestion significantly reduces talinolol bioavailability
-
Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther. 2005;77:291-301.
-
(2005)
Clin Pharmacol Ther
, vol.77
, pp. 291-301
-
-
Schwarz, U.I.1
Seemann, D.2
Oertel, R.3
Miehlke, S.4
Kuhlisch, E.5
Fromm, M.F.6
Kim, R.B.7
Bailey, D.G.8
Kirch, W.9
-
46
-
-
0033093278
-
Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans
-
Schwarz UI, Gramatte T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin Pharmacol Ther. 1999;65:283-90.
-
(1999)
Clin Pharmacol Ther
, vol.65
, pp. 283-290
-
-
Schwarz, U.I.1
Gramatte, T.2
Krappweis, J.3
Berndt, A.4
Oertel, R.5
Richter, O.6
Kirch, W.7
-
47
-
-
40549085349
-
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol
-
Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics. 2008;18:357-65.
-
(2008)
Pharmacogenet Genomics
, vol.18
, pp. 357-365
-
-
Haenisch, S.1
May, K.2
Wegner, D.3
Caliebe, A.4
Cascorbi, I.5
Siegmund, W.6
-
48
-
-
33645028973
-
Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms
-
Bernsdorf A, Giessmann T, Modess C, Wegner D, Igelbrink S, Hecker U, Haenisch S, Cascorbi I, Terhaag B, Siegmund W. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol. 2006;61:440-50.
-
(2006)
Br J Clin Pharmacol
, vol.61
, pp. 440-450
-
-
Bernsdorf, A.1
Giessmann, T.2
Modess, C.3
Wegner, D.4
Igelbrink, S.5
Hecker, U.6
Haenisch, S.7
Cascorbi, I.8
Terhaag, B.9
Siegmund, W.10
-
49
-
-
84924352527
-
The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans
-
Zheng M, Zhang H, Dill DL, Clark JD, Tu S, Yablonovitch AL, Tan MH, Zhang R, Rujescu D, Wu M, et al. The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans. PLoS Med. 2015;12:e1001782.
-
(2015)
PLoS Med
, vol.12
-
-
Zheng, M.1
Zhang, H.2
Dill, D.L.3
Clark, J.D.4
Tu, S.5
Yablonovitch, A.L.6
Tan, M.H.7
Zhang, R.8
Rujescu, D.9
Wu, M.10
-
50
-
-
0029986922
-
Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo
-
Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res. 1996;13:514-22.
-
(1996)
Pharm Res
, vol.13
, pp. 514-522
-
-
Wetterich, U.1
Spahn-Langguth, H.2
Mutschler, E.3
Terhaag, B.4
Rosch, W.5
Langguth, P.6
-
51
-
-
84954326746
-
Heritability of metoprolol and torsemide pharmacokinetics
-
Matthaei J, Brockmoller J, Tzvetkov MV, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Moller S, Halekoh U, Hofmann U, Schwab M, Kerb R. Heritability of metoprolol and torsemide pharmacokinetics. Clin Pharmacol Ther. 2015;98:611-21.
-
(2015)
Clin Pharmacol Ther
, vol.98
, pp. 611-621
-
-
Matthaei, J.1
Brockmoller, J.2
Tzvetkov, M.V.3
Sehrt, D.4
Sachse-Seeboth, C.5
Hjelmborg, J.B.6
Moller, S.7
Halekoh, U.8
Hofmann, U.9
Schwab, M.10
Kerb, R.11
-
52
-
-
84994259443
-
Heritability of caffeine metabolism: Environmental effects masking genetic effects on CYP1A2 activity but not on NAT2
-
Matthaei J, Tzvetkov MV, Strube J, Sehrt D, Sachse-Seeboth C, Hjelmborg JB, Moller S, Halekoh U, Hofmann U, Schwab M, et al. Heritability of caffeine metabolism: Environmental effects masking genetic effects on CYP1A2 activity but not on NAT2. Clin Pharmacol Ther. 2016. doi: 10.1002/cpt.444[Epub ahead of print].
-
(2016)
Clin Pharmacol Ther
-
-
Matthaei, J.1
Tzvetkov, M.V.2
Strube, J.3
Sehrt, D.4
Sachse-Seeboth, C.5
Hjelmborg, J.B.6
Moller, S.7
Halekoh, U.8
Hofmann, U.9
Schwab, M.10
-
53
-
-
84996579470
-
mets: analysis of multivariate event times
-
Holst K, Scheike T. mets: analysis of multivariate event times, R package version 1.1.1. 2015. http://CRAN.R-project.org/package = mets.
-
(2015)
R package version 1.1.1
-
-
Holst, K.1
Scheike, T.2
-
54
-
-
84964927929
-
R: A language and environment for statistical computing
-
Vienna: R foundation for statistical computing
-
R Core Team. R: A language and environment for statistical computing. Vienna: R foundation for statistical computing; 2015. http://www.R-project.org.
-
(2015)
-
-
-
55
-
-
0031826288
-
Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research
-
Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8:283-9.
-
(1998)
Pharmacogenetics
, vol.8
, pp. 283-289
-
-
Kalow, W.1
Tang, B.K.2
Endrenyi, L.3
-
56
-
-
0033044502
-
Repeat administration of drugs as a means to assess the genetic component in pharmacological variability
-
Kalow W, Endrenyi L, Tang B. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology. 1999;58:281-4.
-
(1999)
Pharmacology
, vol.58
, pp. 281-284
-
-
Kalow, W.1
Endrenyi, L.2
Tang, B.3
-
57
-
-
54749128129
-
Validation of a short qualitative food frequency list used in several German large scale surveys
-
Winkler G, Doring A. Validation of a short qualitative food frequency list used in several German large scale surveys. Z Ernahrungswiss. 1998;37:234-41.
-
(1998)
Z Ernahrungswiss
, vol.37
, pp. 234-241
-
-
Winkler, G.1
Doring, A.2
-
58
-
-
0018234075
-
Twin studies in pharmacogenetics
-
Vesell ES. Twin studies in pharmacogenetics. Hum Genet Suppl. 1978;1:19-30.
-
(1978)
Hum Genet
, vol.1
, pp. 19-30
-
-
Vesell, E.S.1
-
59
-
-
0033865280
-
Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein
-
Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther. 2000;68:6-12.
-
(2000)
Clin Pharmacol Ther
, vol.68
, pp. 6-12
-
-
Westphal, K.1
Weinbrenner, A.2
Giessmann, T.3
Stuhr, M.4
Franke, G.5
Zschiesche, M.6
Oertel, R.7
Terhaag, B.8
Kroemer, H.K.9
Siegmund, W.10
-
60
-
-
0000783041
-
Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method
-
Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba ADM. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10:373-88.
-
(2000)
Pharmacogenetics
, vol.10
, pp. 373-388
-
-
Ozdemir, V.1
Kalow, W.2
Tang, B.K.3
Paterson, A.D.4
Walker, S.E.5
Endrenyi, L.6
Kashuba, A.D.M.7
-
61
-
-
0036881077
-
The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol
-
Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther. 2002;72:572-83.
-
(2002)
Clin Pharmacol Ther
, vol.72
, pp. 572-583
-
-
Siegmund, W.1
Ludwig, K.2
Giessmann, T.3
Dazert, P.4
Schroeder, E.5
Sperker, B.6
Warzok, R.7
Kroemer, H.K.8
Cascorbi, I.9
-
62
-
-
2042469487
-
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics
-
Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004;75:415-21.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 415-421
-
-
Mwinyi, J.1
Johne, A.2
Bauer, S.3
Roots, I.4
Gerloff, T.5
-
63
-
-
84963705486
-
Microdosing and other phase-0 clinical trials: facilitating translation in drug development
-
Burt T, Yoshida K, Lappin G, Vuong L, John C, de Wildt SN, Sugiyama Y, Rowland M. Microdosing and other phase-0 clinical trials: facilitating translation in drug development. Clin Transl Sci. 2016;9:74-88.
-
(2016)
Clin Transl Sci
, vol.9
, pp. 74-88
-
-
Burt, T.1
Yoshida, K.2
Lappin, G.3
Vuong, L.4
John, C.5
de Wildt, S.N.6
Sugiyama, Y.7
Rowland, M.8
-
64
-
-
77952239982
-
Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability
-
Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, Garner C. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci. 2010;40:125-31.
-
(2010)
Eur J Pharm Sci
, vol.40
, pp. 125-131
-
-
Lappin, G.1
Shishikura, Y.2
Jochemsen, R.3
Weaver, R.J.4
Gesson, C.5
Houston, B.6
Oosterhuis, B.7
Bjerrum, O.J.8
Rowland, M.9
Garner, C.10
|